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Abstract: The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants
are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a
Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged
significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted
protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3).
Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in
the full dataset (p = 3.17 × 10−4). Importantly, logistic regression analyses conditioning on the main
known MS-associated SNP at this locus, rs17066096, revealed that this association was independent
from the primary association signal in the full case-control dataset. In silico analysis predicted both
disruption of the alpha helix of the H-region of the SP and decreased hydrophobicity of this region,
ultimately affecting the SP cleavage site. We tested the effect of the p.Leu16Pro variant on the secretion
of IL-22BPi1, IL-22BPi2 and IL-22BPi3 and observed that the Pro16 risk allele significantly lowers
secretion levels of each of the isoforms to around 50%–60% in comparison to the Leu16 reference allele.
Thus, our study suggests that genetically coded decreased levels of IL-22BP isoforms are associated
with augmented risk for MS.
Keywords: IL22RA2; IL-22 binding protein isoform; mutation; signal peptide; multiple sclerosis;
autoimmune
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory CNS disorder triggered by environmental
factors in individuals with a susceptible genetic background. Current research implies more than
230 autosomal risk variants, many of which are located within or close to genes exerting functions in
the peripheral immune system or in CNS-resident microglia [1]. Single nucleotide polymorphisms
(SNPs) located at the interleukin-22 receptor subunit alpha-2 (IL22RA2) gene locus were originally
reported to be associated with risk for MS in Scandinavian [2] and Basque [3] populations. A series of
genome-wide association studies (GWAS)-based approaches have subsequently firmly established the
association of IL22RA2 with risk for MS [1,4–6].
The main known function of IL22RA2 is to produce interleukin-22 binding protein (IL-22BP),
a secreted inhibitor of IL-22. IL-22, a member of the IL-10 family, is produced by a wide range of immune
cells and can exert both pro- and anti-inflammatory effects [7,8]. Various lines of evidence suggest that
the IL-22/IL-22BP axis has an important function in MS and neuroinflammation. Il22ra2-deficient mice
experience a more benign course of disease in the experimental autoimmune encephalomyelitis (EAE)
model [9]. The IL-22 receptor is highly expressed in blood–brain barrier (BBB) endothelial cells from
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patients with MS but not in healthy controls, and IL-22 contributes to the permeabilization of the BBB
and recruitment of CD4+ T lymphocytes to the CNS [10]. A decrease of IL-22 levels correlates with the
recovery phase of EAE in rats [11], and serum levels of IL-22 were found to be elevated in MS patients
compared to healthy controls [12]. Perriard et al. [13] demonstrated that IL-22 targets astrocytes in
the human brain and confers increased survival to these cells. They also found higher expression
of IL-22BP mRNA in monocytes and monocyte-derived dendritic cells of MS patients compared to
healthy controls.
IL22RA2 is capable of expressing three partially distinct isoforms that share an identical signal
peptide (SP) at their N-terminus and lack intracellular and transmembrane domains but differ in
their binding capacity of IL-22. Isoform 2 (UniProt nomenclature) shows the highest capacity of
binding and inhibiting IL-22 [14,15], with a 20- to 1000-fold higher affinity than a soluble variant of
the signal-transducing cell surface receptor [16–18]. Isoform 3 has also been demonstrated to bind
IL-22, although with a similar affinity to that of the cell surface receptor [16,19]. Recently, we showed
that the longest isoform, i.e., isoform 1, is not capable of binding IL-22 and displays hallmarks of a
poorly secreted, intracellularly retained protein with intrinsic capacity to trigger the unfolded protein
response (UPR; [20]).
Although the association of IL22RA2 with MS is now established and accumulating evidence
points to an influence of IL-22 and IL-22RA2 in EAE and MS, the mechanism underlying the genetic
association remains elusive. Here, we performed a SNP screen of the IL22RA2 locus in a Basque
population in order to localize the most important association signal(s) within this locus and confirmed
association of an infrequent coding SNP in a European cohort. We used dedicated in silico and wet
experimentation methods to discover potentially causal variants that may explain the association of
this gene with MS.
2. Materials and Methods
2.1. Patients and Controls
All patients were diagnosed with definite MS [21,22]. Written informed consent was obtained from
all subjects, and the study was approved by the local ethics committees. Table 1 shows the clinical and
demographic data of the patients and controls enrolled in this study. The fine-mapping was completed
in the Bilbao dataset, comprising patients registered at the Basurto hospital (Bilbao, Basque Country,
Spain) and controls provided by the Basque BioBank for Research-OEHUN (www.biobancovasco.org).
Additionally, genotyping data of three SNPs (rs276466, rs10484798 and rs6570136) in the Bilbao cohort
were available from the aforementioned screening [3], and these were included in the haplotype and
logistic regression analyses.
The non-synonymous SNP, rs28385692, was further genotyped in additional patients and age-,
gender- and ethnicity-matched controls from Donostia (Instituto Biodonostia, Basque Country, Spain),
Barcelona (Hospital Vall d’Hebron), Madrid (Hospital Clínico S. Carlos), Andalucía (Instituto de
Parasitología y Biomedicina “Lopez-Neyra”), Germany (various centers) and France (various centers)
(Table 1). Considering the SNP with the lowest MAF (rs28385692, 1000G European frequency = 0.032)
and combining all datasets, this study had over 80% statistical power to detect allelic odds ratios
≥ 1.18 with a type-1-error rate of alpha = 0.05 (calculated with the Genetic Power Calculator allelic
test [23]). When considering only the Bilbao dataset, we had over 80% power to detect odds ratios ≥
1.8, assuming a MAF = 0.032 and a type-1-error of alpha = 0.05.
The lead SNP from the 2011 GWAS [6], rs17066096, was also genotyped in all the above-mentioned
validation cohorts, excluding France (Table 1). Additionally, data on the most significantly associated
SNP in the fine mapping, rs202573, were available from Andalucía, Barcelona and Madrid from our
previous study [3], and this SNP was newly genotyped in the Donostia and Germany cohorts.
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Table 1. Clinical and demographic features of patients and controls included in the genetic study. 1
SD: standard deviation. 2 RR: relapsing remitting MS. 3 ScP: secondary progressive MS. 4 PP: primary
progressive MS. 5 ND: not determined. 6 EDSS: expanded disability status scale.
Population Number(% Female)
Age, Average
± SD 1
RR 2 & ScP 3/
PP 4/Other/ND 5
Age at Onset,
Average ± SD
EDSS 6,
Mean ± SD
Bilbao
Cases 647 (72.3) 42.5 ± 12.01 79.6/9/1.4/10 30.42 ± 10.17 2.9 ± 2.3
Controls 573 (60.3) 44.2 ± 9 - - -
Donostia
Cases 572 (64.8) 46.4 ± 4.8 84.8/3.8/4.8/6.6 33.01 ± 11.05 2.79 ± 2.7
Controls 250 (66) 50.52 ± 13.26 - - -
Barcelona
Cases 676 (63.3) 40.17 ± 12.93 81.5/14.8/3.7 31.6 ± 9.9 3.91 ± 2.5
Controls 910 (52.7) 40.2 ± 12.9 - - -
Madrid
Cases 899 (63.7) 44.8 ± 10.55 79.7/6.9/4.7/8.7 29.8 ± 8.65 2.56 ± 2.13
Controls 697 (55.1) 40.96 ± 16.71 - - -
Andalucía
Cases 1474 (61) 43 ± 12 47.4/1/9/42.6 28.87 ± 10.25 ND
Controls 1777 (64.4) 40.22 ± 12.9 - - -
Germany Cases 3762 (70.2) 42.2 ± 13.6 ND ND ND
Controls 2972 (60.1) 41.1 ± 14.05 - - -
France
Cases 1344 (63.6) 44.3 ± 11.8 ND ND ND
Controls 768 (60.4) 39.6 ± 13 - - -
2.2. Selection and Genotyping of SNPs
Ten haplotype-tagging SNPs were selected based on genotype data from the CEU + TSI population
(HapMap release #27) using an r2 cut-off = 0.9 and a MAF = 0.1 (with the Multimarker Tagger Algorithm
available on the HapMap website, www.hapmap.org, now defunct). In addition, SNP rs13217897 was
selected based on its association with MS as reported by an independent group [2], and rs28385692
was included because of its potential functional effect, given its location in the coding region.
Haplotype-tagging SNPs in the Bilbao cohort and rs28385692 in the Donostia cohort were genotyped
using the iPLEX Sequenom MassARRAY platform in the Spanish National Genotyping Center
(CEGEN, Santiago de Compostela, Spain, www.cegen.es). Genotyping of rs17066096, rs202573 and
rs28385692 in the validation cohorts was performed using Taqman® Genotyping Assays, following the
manufacturer’s instructions. The genotyping efficiency was above 95% in all datasets, and all SNPs
were in Hardy–Weinberg equilibrium in controls in each dataset.
2.3. Statistical Analysis
The statistical analysis was performed using PLINK v1.07 (http://zzz.bwh.harvard.edu/plink/) [24].
For the association analysis, a logistic regression with an additive model, adjusted for sex, was applied.
The independence of association signals was assessed using a conditional logistic regression analysis.
A chi-squared test was used to check for the Hardy–Weinberg equilibrium. A haplotype analysis was
performed using Haploview v.4.2 (https://www.broadinstitute.org/haploview/haploview) [25]. Only the
samples that had genotyping data available for all the SNPs were used for the haplotype calculation
(for the Bilbao cohort, 375 cases and 441 controls; for the joint datasets, 6545 cases and 5713 controls).
Haplotype blocks were defined by the confidence interval method [26]. Permutations were applied
(n permutations = 1000) to correct for multiple comparisons in the haplotype analysis. Statistical
power was calculated using the CaTS power calculator at www.sph.umich.edu/csg/abecasis/CaTS/ [27].
Secretion levels of Leu16 IL-22BP isoforms compared to those of Pro16 variants were compared used
Student’s unpaired t-test.
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2.4. Functional Annotation of SNPs
Each of the associated SNPs and their proxies (r2 ≥ 0.8 in European populations of the 1000
Genomes pilot project as retrieved from the SNAP Proxy Search tool (https://www.broadinstitute.
org/mpg/snap/) [28] were functionally annotated using the Ensembl Variant Effect Predictor (VEP)
(https://www.ensembl.org/info/docs/tools/vep/index.html) [29] and the RegulomeDB (http://www.
regulomedb.org/) [30].
2.5. In silico Analysis of the Effect of the Leu to Pro Transition Coded by rs28385692 on Signal Peptide
Characteristics
PredictSNP web server (https://loschmidt.chemi.muni.cz/predictsnp1/) [31], Meta-SNP
(http://snps.biofold.org/meta-snp/) [32] and Ensembl VEP tool (http://www.ensembl.org/Homo_
sapiens/Variation/Mappings?db=core;r=6:137161203-137162203;v=rs28385692;vdb=variation;vf=
104559210#ENST00000296980_104559210_G_tablePanel) [29,33] were used to estimate the functional
effect of p.Leu16Pro mutation on IL-22BP. The SignalP 3.0 [34], Phobius [35], PsiPred [36], SignalP 5.0
(http://www.cbs.dtu.dk/services/SignalP/) [37], PrediSi [38], and Signal-3L tools were used to predict
the effects of the p.Leu16Pro substitution on SP function in IL-22BP. Secondary structure features of the
wildtype/mutant proteins were predicted by PsiPred [39], RaptorX (http://raptorx.uchicago.edu/) [40]
and SABLE [41].
2.6. p.Leu16Pro Mutagenesis of the Three IL-22BP Isoforms
The expression plasmid for IL22RA2v1 was constructed as described in our previous work [20],
IL22RA2v2 and IL22RA2v3 expression plasmids were purchased from OriGene Technologies (RC219095,
Rockville, MD, USA) and GenScript (Ohu00490, Piscataway, NJ, USA), respectively. The p.Leu16Pro
mutants of IL-22BPi1, 2 and 3 were generated using the GENEART® site-directed mutagenesis system
(A13282, Invitrogen, Waltham, MA, USA) from the IL22RA2v1, 2 and 3 expression plasmids following
the manufacturer’s instructions. The site-directed mutagenesis primer design was also done following
the manufacturer’s instructions. Briefly, both primers contained the desired mutation centrally located
and were 100% complementary with no overhangs, and with lengths between 30 and 45 nucleotides.
The designed primers, purchased from IDT, were purified by HPLC to increase mutagenesis efficiency.
PCR was performed using a Verity thermocycler (Applied Biosystems, Waltham, MA, USA) with the
following primers: IL22RA2_p.Leu16Pro_FW: 5′-TCATCAGTTTCTTCCCTACTGGTGTAGCAGG-3′
and IL22RA2_p.Leu16Pro _RV: 5′-CCTGCTACACCAGTAGGGAAGAAACTGATGA-3′. The PCR
conditions used were: 1 cycle at 37 ◦C for 20 min and 94 ◦C for 45 s, 18 cycles at 94 ◦C for 45 s,
57 ◦C for 45 s and 72 ◦C for 6 min, 1 cycle at 72 ◦C for 10 min and a final holding stage at 4 ◦C.
The resulting constructs were sequenced to confirm point mutations of IL22RA2 variant constructs.
The p.Leu16Pro mutant plasmids were transformed into DH5α-T1R E. coli competent cells following
the manufacturer’s instructions. Plasmids were purified with EndoFree Plasmid Kit (Qiagen, Hilden,
Germany), quantified by a NanoDrop Spectrophotometer (ThermoFisher Scientific, Waltham, MA,
USA) and visually assessed via agarose gel electrophoresis.
2.7. Assessment of Effect of p.Leu16Pro Variant on Secretion of IL-22BP Isoforms
HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM: D5796, Sigma,
St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; F9665, Sigma, St. Louis,
MO, USA) at 37 ◦C and 5% CO2 in a humidified incubator. Cells were seeded on a 24-well plate at
500 µL/well at a density of 3 × 104 cells/well. Cells were transfected with the indicated expression
plasmids when they reached 60%–70% confluency using MACSfectin Reagent (130-098-412, Miltenyi,
Bergisch Gladbach, Germany). Twenty-four hours after transfection, conditioned media were collected
and cells washed three times with cold PBS prior cell lysis in RIPA buffer (25 mM Tris-HCl, 150 mM
NaCl, pH 7.6; plus 1% N-40, 1% sodium deoxycholate, and 0.1% SDS) in the presence of protease
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inhibitors (11697498001, Roche, Basel, Switzerland). All cell lysates were quantified for total protein
using BCA kit (23225, ThermoFisher Scientific); equal amounts of total protein were resuspended
in reducing loading buffer and resolved on SDS-PAGE for further immunoblotting. For acetone
precipitation of conditioned media, 4 h prior media collection, cells were carefully washed five times
with pre-warmed serum-free medium (SFM; 12-764Q, Lonza, Basel, Switzerland) to remove serum
proteins and SFM supplemented with L-glutamine (G5792, Sigma) was added for a further 4 h.
Conditioned SFM were acetone precipitated with four volumes of ice-cold acetone and incubated on
ice for 10 min followed by centrifugation at 21,000× g a 4 ◦C. Pellets were resuspended in reducing
loading buffer and resolved on SDS-PAGE for further immunoblotting. The antibodies used in this
study are the following: anti-FLAG (1:1000; 2043-1-AP, Proteintech, Rosemont, IL, USA); anti-IL-22BP
(1:1000; AF1087 and BAF1087, R&D Systems, Minneapolis, MN, USA); anti-IL-22BP (1:1000; ab133965,
Abcam, San Francisco, CA, USA); anti-tubulin (1:1000; A01490, GenScript, Piscataway, NJ, USA) and
all HRP-conjugated secondary antibodies were purchased from Jackson ImmunoResearch. IL-22BP
ELISA capable of detecting the three isoforms was performed as previously described [20].
2.8. Replacement of the SP of IL-22BPi2 with the IL17A SP
The IL17SP_IL22RA2v2 construct was generated from two overlapping fragments; the first
one containing the terminal SgfI restriction site followed by the sequence of the SP of IL-17A
and the beginning of IL-22BPi2 mature protein, and the second one, containing the end of
IL-17A SP followed by IL-22BPi2 mature protein flanked by Mlu restriction site. The overlapping
fragment was amplified and digested with SgfI and MluI restriction enzymes and cloned into
pCMV6-Entry vector. Primers for amplification of the IL17A_Signal peptide fragment were: FW:
5′-GCCGCGATCGCCATGACTCCTGGGAAGACC-3′ and RV:5′-AGGCTTCAGAGACTCATGCG
TTGACTGAGTGATTGTGATTCCTGCCTTCACTATGGCCTCCAGGCTC-3′. Primers for amplification
of the IL22RA2v2 mature fragment were: FW 5′-GAGCCTGGAGGCCATAGTGAAGGCAGGAATCA
CAATCACTCAGTCAACGCATGAGTC TCTG-3′ and RV: 5′-CGTACGCGTTGGAATTTCCACACA
TCTCTC-3′.
2.9. Flow Cytometry Analysis
HEK293 cells were transfected with expression vectors for wild-type or p.Leu16Pro mutant
IL-22BPi2, collected after 24 h and washed with flow cytometry buffer (FC Buffer; PBS, 0.5% BSA and
2mM EDTA, pH 7.2). Single cell suspensions were fixed with 4% paraformaldehyde for 10 min at room
temperature followed by permeabilization with 90% of ice-cold methanol for 30 min at 4 ◦C. Cells were
blocked with 1% BSA for 15 min at RT, incubated with anti-IL-22BP primary antibody (1:250; 66190,
Proteintech) for 30 min at room temperature and followed by another 30-minute incubation period
with anti-mouse-FITC conjugated secondary antibody (1:500; AMI4608, ThermoFisher) protected from
light. Two washes were performed after each step with FC buffer. Immunostained cells were analyzed
using a MACSQuant Analyzer (Miltenyi).
3. Results
3.1. The p.Leu16Pro coding SNP rs28385692 is Associated with Risk for Multiple Sclerosis
A total of 15 SNPs in a ~100-kb interval around IL22RA2 were analyzed in the Bilbao cohort.
Of these, five showed nominally significant (p < 0.05) association with MS (Figure 1, Table 2). The most
strongly associated SNP was rs202573 (OR = 1.27, p = 0.007), which had already been the index SNP in
the initial screening [3]. This intronic SNP is in weak LD in the Bilbao dataset (r2 = 0.06, D’ = 0.31)
with the most significant GWAS-derived top SNP found at the IL22RA2 locus, i.e., rs17066096 [1,4–6].
Rs17066096 showed no association in the Bilbao dataset. Logistic regression analysis of all SNPs
conditioning on rs202573 did not reveal any other independent SNP signal reaching statistical
significance including rs17066096, suggesting that the main effect observed in this population is driven
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by rs202573 (Appendix A Table A1). Haplotype analysis did not show any haplotype displaying a
higher significance than single SNPs in the IL22RA2 region (Table A2).Cells 2019, 8, x FOR PEER REVIEW 7 of 23 
 
Figure 1. A single nucleotide polymorphism (SNP) screen of the IL22RA2 locus in the Bilbao dataset. 
SNPs, depicted with dots in different colors depending on r2 values with respect to the index SNP 
rs202573, are plotted as a function of their log-converted p-value (left Y axis) and their position on 
chromosome 6 according to hg19 assembly of the human genome (X axis). The recombination rate 
across the locus is provided on the right Y axis. The red line represents the significance threshold (p = 
0.05). SNPs genotyped in the primary screening [3] are shown in italics. rs202573, which was 
genotyped both in the previous and in the present study, is underlined. 
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Bilbao cohort, the C allele was present only in one haplotype, which contained the risk alleles of four 
additional SNPs that displayed significant associations in the Bilbao dataset (Figure A1). The 
association of rs28385692 with MS strengthened when adding 250 controls and 572 cases from 
nearby Donostia to our analysis, also located in the Basque Country (p = 0.03, OR = 1.88, 95% CI = 
Figure 1. A single nucleotide polymorphism (SNP) screen of the IL22RA2 locus in the Bilbao dataset.
SNPs, depicted with dots in different colors depending on r2 values with respect to the index SNP
rs202573, are plotted as a function of their log-converted p-value (left Y axis) and their position on
chromosome 6 according to hg19 assembly of the human genome (X axis). The recombination rate
across the locus is provided on the right Y axis. The red line represents the significance threshold
(p = 0.05). SNPs genotyped in the primary screening [3] are shown in italics. rs202573, which was
genotyped both in the previous and in the present study, is underlined.
Table 2. Association values of SNPs included in the mapping analysis in the Bilbao dataset. 1 Position
is according to he hg19 genome build. 2 RAF: risk allele frequency. 3 OR: o ds ratio. 4 CI:
confidence in erval.
SNP Position 1 Risk Allele RAF 2 Cases RAF Controls Other Allele p OR 3 (95% CI 4)
rs4896239 137,448,873 C 0.52 0.50 T 0.19 1.116 (0.942–1.31)
rs17066096 137,452,908 G 0.29 0.27 A 0.26 1.132 (0.92–1.34)
rs12194034 137,458,262 A 0.23 0.22 T 0.65 1.047 (0.86–1.274)
rs1543509 137,465,656 C 0.15 0.14 T 0.92 1.012 (0.797–1.285)
rs28366 137,466,087 C 0.24 0.23 T 0.52 1.066 (0.88–1.297)
rs276466 137,466,614 A 0.78 0.78 G 0.99 1.001 (0.799–1.25)
rs10484798 137,470,756 A 0.76 0.72 G 0.05 1.23 (1.0–1.508)
rs13217897 137,471,327 G 0.83 0.79 A 0.02 1.291 (1.05–1.591)
rs202573 137,473,672 A 0.33 0.28 G 0.007 1.273 (1.067–1.518)
rs2064501 137,477,823 T 0.50 0.49 C 0.65 1.039 (0.879–1.226)
rs11154914 137,480,411 G 0.19 0.16 A 0.06 1.23 (0.99–1.524)
rs28385692 137,482,840 C 0.02 0.01 T 0.05 1.972 (0.983–3.954)
rs13197049 137,491,211 A 0.83 0.80 T 0.03 1.260 (1.021–1.556)
rs6570136 137,494,622 A 0.46 0.45 G 0.85 1.017 (0.847–1.222)
rs7745487 137,496,672 A 0.18 0.15 G 0.10 1.201 (0.96–1.496)
I terestingly, an infrequent non-synonymous SNP (rs28385692; changes Leu to Pro at position 16
of the SP shared by the three IL-22BP isoforms) was at the limit of statistical significance in the Bilbao
dataset (Figure 1 and Table 2; p = 0.05, OR = 1.972, 95% CI = 0.983–3.954). The risk allele of this SNP (C)
is comparatively rare (MAF = 0.015). Notably, haplotype analyses of all genotyped SNPs revealed that
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among all the haplotypes that were present with a frequency higher than 0.5% in the Bilbao cohort,
the C allele was present only in one haplotype, which contained the risk alleles of four additional
SNPs that displayed significant associations in the Bilbao dataset (Figure A1). The association of
rs28385692 with MS strengthened when adding 250 controls and 572 cases from nearby Donostia to
our analysis, also located in the Basque Country (p = 0.03, OR = 1.88, 95% CI = 1.08–3.282). Next,
we validated this finding in independent Spanish and European cohorts comprising a total of 8960
cases and 7613 controls. The joint analysis of the discovery and validation cohorts confirmed the
association of rs28385692 with MS (p = 3.6 × 10−4, OR = 1.262, 95% CI = 1.11–1.434 (Figure 2a).
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Figure 2. Forest plots representing effect size estimates (OR, 95% confidence interval) of the risk alleles
of rs28385692 (a), rs202573 (b) and rs17066096 (c) in the study populations: Central Spain (Madrid
area), South of Spain (Andalucía), North of Spain (Basque Country), East of Spain (Barcelona area),
Germany, and France, and in the combined dataset. The dots’ size is proportional to the sample size of
each population.
To further delineate the findings of this mapping effort, our original index SNP, rs202573, and the
GWAS-derived top SNP, rs17066096 [4,6], were also genotyped in all validation datasets except France.
Upon combining all available datasets, we found a significant association of rs17066096 (p = 9.9 × 10−5,
OR = 1.11, 95% CI = 1.054–1.172), but not rs202573 (p = 0.12, OR = 1.04, 95% CI = 0.99–1.09) (Figure 2b,c).
Logistic regression analysis on the combined datasets revealed that the associations of rs17066096 and
rs28385692 are statistically independent, since conditioning on one SNP did not abolish association
of the other (Table 3). None of the haplotypes formed by these three SNPs increased the statistical
evidence for association compared to the single SNPs in the combined datasets, but, as seen in the
dataset from Bilbao, the C allele of the infrequent SNP rs28385692 appeared only in the same haplotype
as the risk alleles of the other two SNPs (Figure A2).
Table 3. Association values of the three SNPs in the discovery + validation datasets conditioned on
rs17066096 and rs28385692. 1 OD: odds ratio. 2 CI: confidence interval.
Conditioned to rs17066096 Conditioned to rs28385692
SNP Reference (minor) Allele p OR 1 (95% CI 2) p OR (95% CI)
rs17066096 G NA NA 0.001042 1.098 (1.039–1.162)
rs202573 A 0.2424 1.029 (0.981–1.079) 0.3093 1.033 (0.9702–1.1)
rs28385692 C 0.001146 1.098 (1.101–1.476) NA NA
We next attempted to define which of the associated SNPs were most likely to have functional
effects based on in silico predictions. To this purpose, we analyzed the five significant variants from
the original Bilbao SNP screen and SNPs that were significantly associated in the validation effort,
i.e., rs17066096 and rs28385692, using VEP and RegulomeDB (Table 4). As this study was based on
a haplotype-tagging method, the observed association signals were considered to be representative
of SNPs in linkage disequilibrium (LD) with the associated markers, and therefore, proxies for the
associated SNPs were also included in the analysis. Neither rs202573, the most associated SNP in the
Bilbao dataset, nor the only proxy of this SNP which met the r2 threshold (r2 = 0.8) to be included in
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the analysis, were predicted to overlap with any regulatory feature. rs17066096 did not show evidence
to be functional either, but two of its perfect proxies (r2 = 1), rs17066063 and rs62420820, displayed
a moderate regulatory potential based on RegulomeDB. rs17066063 was the SNP with the highest
regulatory potential based on concordance between RegulomeDB (score 3a) and VEP (consequence:
TF binding site variant). rs28385692 was predicted to lie within a regulatory region, although the level
of evidence supporting this is modest (score 5 according to RegulomeDB).
Table 4. Functional predictions of associated SNPs and proxies. SNPs with significant associations in
the mapping exercise or in the discovery + validation cohorts and their proxies (r2 > 0.8 in 1000 Genomes
Phase III CEU population) were assessed using VEP and RegulomeDB. 1 Minor allele frequency is
based on European populations in the 1000 Genomes Project Phase III.
SNP Proxy MajorAllele
Minor Allele
(Frequency) 1
Ensembl
Consequence SIFT PolyPhen RegulomeDB
rs10484798
rs28362847 G A (0.21) regulatory_region_variant - - 5: TF binding orDNase peak
rs10484798 G A (0.21) intron_variant - - 6: other
rs13197049
rs13217897 G A (0.17) intron_variant - - 3a: TF binding + anymotif + DNase peak
rs17175239 A G (0.17) intergenic_variant - - 5: TF binding orDNase peak
rs1961618 C T (0.17) intron_variant - - 5: TF binding orDNase peak
rs12664889 C A (0.17) intron_variant - - 7: no data
rs13197049 A T (0.17) intron variant - - 7: no data
rs11154913 A G (0.17) intron_variant - - 5: TF binding orDNase peak
rs13193435 C A (0.17) intron_variant - - 5: TF binding orDNase peak
rs7749054 T G (0.17) intergenic_variant - - 6: other
rs13197049 A T (0.17) intron_variant - - 7: no data
rs7766677 A C (0.17) intergenic_variant - - 7: no data
rs13217897
rs13217897 G A (0.17) intron_variant - - 3a: TF binding + anymotif + DNase peak
rs13193435 C A (0.17) intron variant - - 5: TF binding orDNase peak
rs1961618 C T (0.17) intron_variant - - 5: TF binding orDNase peak
rs17175239 A G (0.17) intergenic_variant - - 5: TF binding orDNase peak
rs7766677 A C (0.17) intergenic_variant - - 6: other
rs11154913 A G (0.17) intron_variant - - 7: no data
rs7749054 T G (0.17) intergenic_variant - - 7: no data
rs12664889 C A (0.17) intron_variant - - 7: no data
rs13197049 A T (0.17) intron_variant - - 7: no data
rs17066096
rs17066063 G A (0.23) TF_binding_site_variant - - 3a: TF binding + anymotif + DNase peak
rs62420820 G A (0.23) regulatory_region_variant - - 3a: TF binding + anymotif + DNase peak
rs72975618 C T (0.23) TF_binding_site_variant - - 4: TF binding +DNase peak
rs1322553 A G (0.23) regulatory_region_variant - - 5: TF binding orDNase peak
rs12214115 G T (0.23) regulatory_region_variant - - 5: TF binding orDNase peak
rs12214014 C T (0.23) regulatory_region_variant - - 5: TF binding orDNase peak
rs17066096 A G (0.23) intergenic_variant - - 6: other
rs202573
rs202571 T C (0.31) intron_variant - - 7: no data
rs202573 G A (0.31) intron_variant - - 7: no data
rs28385692 rs28385692 T C (0.03) missense_variant Tolerated(0.11)
Benign
(0.376)
5: TF binding or
DNase peak
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3.2. In Silico Analysis of the p.Leu16Pro Variant
We evaluated in silico whether rs28385692 is functionally neutral or deleterious by using
computational tools based on different approaches [42]; i.e., PredictSNP [31], Meta-SNP [32] and
Ensembl VEP tool [29,33]. A summary of the features of each tool used in this study is represented
in Table A3. PredictSNP indicated that the overall result of the p.Leu16Pro transition in the SP was
deleterious for all three isoforms (Figure A3a). However, Meta-SNP [32] anticipated a neutral effect
for the p.Leu16Pro point mutation in all IL-22BP isoforms (Figure A3b). Finally, the pathogenicity
prediction tools included in Ensembl VEP tool predicted the substitution not to be deleterious except
for a sub-analysis based on the Mutation Assessor tool available in Ensembl VEP, which attributed
a medium level of functional impact to this variant (Figure A3c). Thus, the overall results obtained
with the computational tools were not robust enough to unequivocally assign a functional effect to
the p.Leu16Pro variant. As this variant occurs in the SP of IL-22BP protein, its potential effect on
structural aspects pertinent to SP biological function per se was assessed in more detail by in silico
methods. Coding SNPs in signal peptides may alter translocation efficiency, cleavage sites, as well
as post-cleavage events [43]. We analyzed the charge, the hydrophobicity, and the helix-breaker
amino acid residues comprised in the SP of IL-22PB, as well as the modifications introduced by
the p.Leu16Pro variant (Figure 3). The Leu16 residue is one of three leucines that contribute to the
IL-22BP SP hydrophobic core H-region, a stretch of hydrophobic amino acids with propensity to form
a single alpha-helix. However, its replacement, Pro16, is a helix-breaker neutral residue with restricted
conformational flexibility that has no free hydrogen to contribute to helix stability. Results obtained
with various signal peptide cleavage site and secondary structure prediction tools are represented
in Figure 3a. While SignalP-3.0 [34] and PSIPRED [36] did not predict any change in the cleavage
site, Phobius [35] predicted the p.Leu16Pro polymorphism to shift the signal peptide cleavage site
from the 21st to 20th residue. The three software applications coincided in predicting a shortening
of the hydrophobic core of the signal peptide. Other prediction tools were applied as well and these
predicted similar structural effects (Figure A4).
3.3. The p.Leu16Pro Variant Decreases Secretion of IL-22BPi1, IL-22BPi2 and IL-22BPi3
To experimentally verify the effect of this variant on secretion, we performed site-directed
mutagenesis to change Leu16 to Pro in the signal peptide of the three wild-type IL-22BP isoforms
cloned in expression vectors reported before [20]. HEK293 cells were individually transfected with these
vectors, and both intracellular and secreted levels of IL-22BPi1, IL-22BPi2 and IL-22BPi3 were measured
by ELISA. Compared to Leu16, Pro16 strongly decreased the secreted levels of each isoform (Figure 4a).
This was mirrored by nonsignificant trends towards decreased intracellular levels of IL-22BPi1 and
IL-22BPi2. Cell lysates as well as acetone precipitates of conditioned medium of HEK293 cells
transfected to produce Leu16 or Pro16 forms of IL-22BPi1 and IL-22BPi2 were analyzed by immunoblot
and this revealed decreased intracellular (51 kDa for IL-22BPi1 and 48 kDa for IL-22BPi2) and secreted
(56 kDa for IL-22BPi2) levels of the mutant forms (Figure 4b), while transfection efficiencies as measured
by RT-qPCR through quantification of mRNA levels were similar (Figure 4c). These observations
are compatible with the effects predicted by the above in silico analysis, suggesting that the Pro16
variant renders import of the precursor IL-22BP isoforms into the endoplasmic reticulum less efficient.
Flow cytometry analysis also revealed a decrease of 41% to 33% in IL-22BP+ cells following transfection
of HEK293 with Leu16 or Pro16 vectors encoding IL-22BPi2, respectively (Figure A5). We also assessed
the efficiency of the native signal peptide of IL-22BPi2 in facilitating secretion by replacing it with that
of IL-17, an efficiently secreted protein [20]. This modification resulted in much higher levels of both
intracellular and secreted IL-22BPi2 (Figure 5), suggesting that the wild-type IL-22BP signal peptide is
less efficiently engaged by the co-translational targeting and translocation machinery across the ER
membrane than that of IL-17, which may affect overall IL-22BP biogenesis [44].
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Figure 3. Prediction of the effect of the p.Leu16Pro amino acid change on the IL-22BP signal peptide 
structure and cleavage site of mature IL-22BP. (a) The signal peptide cleavage site indicated with 
green (wt, Leu16) or red (Pro16) arrows, was predicted using SignalP-3.0, Phobius and PsiPred 
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ff
and cleavage site of mature IL-22BP. (a) The signal peptide cleavage site indicate with green
(wt, Leu16) or red (Pro16) ar ws, was predicted using SignalP-3.0, Phobius and PsiPred software.
The cleavage sit for the can nical sequence is pr dicted to oc ur between positions 21 and 22 by the
three softwa applications used. The p.L u16Pro variant causes a shift in the predicted cleavage site
to betw en position 20 and 21 accordi g to Phobius bu not SignalP 3.0 and PsiPred each of which
predicted identical cleavage sites to the canonical sequence. All software coincided in predicting a
decrease in the length of the H-region in the mutant form. (b) Representation of the composition,
hydrophobicity and charge of the amino acids that comprise the signal peptide of IL-22BP. The three
domain structures of the IL-22BP signal peptide are represented based on the overall results obtained
in (a), and consist of the N-region, a hydrophilic positively charged N-terminal region; the H-region,
a hydrophobic core region; and the C-region, a polar uncharged C-terminal region that is recognized by
signal peptidase.
4. Discussion
In this study, we identified an infrequent functional variant (rs28385692) in IL22RA2, which confers
risk to MS independently of the major GWAS-derived signal, and we were able to show that this variant
has immediate functional effects by reducing secreted IL-22BP levels in transfected HEK293 cells.
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Figure 4. The Pro16 variant in the SP of the thr e IL- 2BP isoforms is a sociated with decreased
secretion levels compared to the Leu16 variant. (a) HEK293 cells were transfected with the indicated
expre sion plasmids, 24 h later cells were lysed and the conditioned medium collected. Intracellular
and secreted IL-22BP isofor re easured by ELISA (mean ± SEM; n = 3; p-values by
unpaired t-test). (b) HEK293 cells were transfect d with e indicated xpression plasmids, 24 h later
c lls were lysed and the conditioned medium was subject d to acetone precipitation (AP). Both cell
lysate (CL) and AP were resolv d by SDS-PAGE under non-reducing conditions and immunoblotted
against FLAG (Ponceau staining served as loading contro ). For AP, the immunoblot membrane was
subjected to longer xposure tim s. (c) HEK293 c lls were transiently transfected wi h the indi ated
expression vectors (EV denotes empty vector), 24 h later cells were lysed and RNA purified. Intracellular
IL-22BP protein w s immunoaffinity-purified with FLAG agaroses and detected by WB following
FLAG purification and in cell lysates (CL) and pass through fraction (PT). GRP94 detection nd Ponceau
staining served as loading controls. Transfection efficiency was measured by IL22RA2 RT-qPCR relative
to the housekeeping gene ACTB. Mean ± SEM of three tech ical replicates. Note that as previously
observed [20], immunoreactive bands corresponding to intracellular IL-22BP isoforms appear as a
series of 43 to 56 kDa bands due to differential N-glycosylation, with secreted IL-22BPi2 gaining ~8 kDa
(56 vs. 48 kDa) due to complex N-glycosylation.
SNP rs28385692, located in exon 2 of IL22RA2, changes the amino acid in position 16 of the
protein from leucine to proline. This change occurs in the SP shared by the three IL-22BP isoforms
produced by IL22RA2. In silico prediction methods diverged in their capacity to assign a functionally
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relevant effect on protein function to this variant. However, various in silico structural assessment
methods coincided in predicting a shortening of the hydrophobic H-region of the IL-22BP SP by the
16P residue that may influence the precise location of the cleavage site with the mature portion of the
IL-22BP proteins. Importantly, in this study, we went beyond the in silico predictions by assessing the
effect of rs28385692 in vitro and showed experimentally using transfected cells that the p.Leu16Pro
mutation significantly reduced the secreted levels of the IL-22BPi1, IL-22BPi2 and IL-22BPi3 isoforms.
Specifically, the risk allele of p.Leu16Pro lowers secretion levels of each isoform to around 50%–60% of
those of the respective wild-type isoforms as quantified using ELISA.Cells 2019, 8, x FOR PEER REVIEW 13 of 23 
 
Figure 5. Native signal peptide of IL-22BP does not efficiently mediate secretion of IL-22BPi2. 
HEK293 cells were transfected with IL-17, IL-22BPi2, and IL-17SP_IL-22BPi2 expression plasmids, 
and 24 h later, cells were lysed and the conditioned medium subjected to acetone precipitation (AP). 
Both cell lysates (CL) and AP were resolved by SDS-PAGE under non-reducing conditions and 
immunoblotted against FLAG, IL-22BP and using tubulin as loading control. Intracellular IL-22BP 
reactive bands relative to tubulin ones were scanned and represented as fold change to IL-22BP 
wild-type (mean ± SD, n = 2). 
4. Discussion 
In this study, we identified an infrequent functional variant (rs28385692) in IL22RA2, which 
confers risk to MS independently of the major GWAS-derived signal, and we were able to show that 
this variant has immediate functional effects by reducing secreted IL-22BP levels in transfected 
HEK293 cells. 
SNP rs28385692, located in exon 2 of IL22RA2, changes the amino acid in position 16 of the 
protein from leucine to proline. This change occurs in the SP shared by the three IL-22BP isoforms 
produced by IL22RA2. In silico prediction methods diverged in their capacity to assign a 
functionally relevant effect on protein function to this variant. However, various in silico structural 
assessment methods coincided in predicting a shortening of the hydrophobic H-region of the 
IL-22BP SP by the 16P residue that may influence the precise location of the cleavage site with the 
mature portion of the IL-22BP proteins. Importantly, in this study, we went beyond the in silico 
predictions by assessing the effect of rs28385692 in vitro and showed experimentally using 
transfected cells that the p.Leu16Pro mutation significantly reduced the secreted levels of the 
IL-22BPi1, IL-22BPi2 and IL-22BPi3 isoforms. Specifically, the risk allele of p.Leu16Pro lowers 
secretion levels of each isoform to around 50%–60% of those of the respective wild-type forms as 
quantified using ELISA. 
Figure 5. Native signal peptide of IL-22BP does not efficiently mediate secretion of IL-22BPi2. HEK293
cells were transfected with IL-17, IL-22BPi2, and IL-17SP_IL-22BPi2 expression plasmids, and 24 h later,
cells were lysed and the conditioned medium subjected to acetone precipitation (AP). Both cell lysates
(CL) and AP were resolved by SDS-PAGE under non-reducing conditions and immunoblotted against
FLAG, IL-22BP and using tubulin as loading control. Intracellular IL-22BP reactive bands relative to
tubulin ones were scanned and represented as fold change to IL-22BP wild-type (mean ± SD, n = 2).
The literature documents several examples of similar changes in signal peptides that have been
proven to affect secretion and are related to human diseases or traits: a Leu->Pro mutation in the
signal peptide of COL5A1 (Alpha 1 Type V Collagen), a subunit of type V collagen, caused retention
of this subunit in the endoplasmic reticulum and was associated with Ehlers-Danlos syndrome,
a heritable connective tissue disease, in two unrelated families [45]. In addition, a common SNP
causing a Leu->Pro mutation in the prohormone region of NPY (Neuropeptide Y) caused an increased
secretion of this protein in chromaffin cells [46]. The inverse case, i.e., a change from proline to leucine,
has also been reported to affect protein secretion: a Pro->Leu mutation in the signal peptide of DSPP
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(Dentin Sialophosphoprotein) resulted in a defective secretion of this protein and was associated with
dentinogenesis imperfecta type III in a Korean family [47]. Finally, a Thr->Pro variant associated with
coronary artery disease risk, located in the SP of the lysosomal acid lipase gene (LIPA), yields reduced
LIPA protein levels and activity due to enhanced degradation [48].
The logistic regression analysis showed that associations of rs28385692 and the main IL22RA2
GWAS SNP, rs17066096, with MS may be statistically independent. This suggests that there are at
least two different variants causing association with MS within the IL22RA2 locus: one presumably
corresponding to rs28385692 and the other one to a SNP in LD with rs17066096. rs17066096 itself is
unlikely to be a causative variant, based on its intergenic location and its missing functional effect in
our extensive in silico annotations. Recently, Lill and colleagues made an attempt to discover possible
causal variants in LD with rs17066096. They performed an in silico and in vitro analysis of SNPs in the
3′UTR of IL22RA2 that were at least in moderate LD with rs17066096 (r2 > 0.3) predicted to affect the
binding of micro-RNAs (miRNAs; [49]). Although they successfully identified one SNP in a miRNA
binding area, they did not find allele-specific differences on this binding; therefore, association of
rs17066096 with MS remains unexplained. Despite these non-confirming functional data of Lill et
al., rs17066063 might be a reasonable candidate for future functional studies given its location in a
regulatory region of the gene.
Our study has several limitations. Firstly, in certain sub-analyses (e.g., individual populations),
our study may have been underpowered to detect modest effects. Secondly, we restricted our analyses
to individuals of European descent, which was self-reported. Thus, residual confounding due to
undetected population stratification may have impacted some of our results and may account for some
of the heterogeneity of the observed effect estimates. However, the effect size for the GWAS-derived
SNP rs17066096 estimated in our datasets (OR = 1.11) was very similar to the one described in the
original GWAS (OR = 1.14) [4–6], suggesting that the impact of population substructure on our results is
minor. Lastly, observing both genetic risk association and an effect of the genotypes on gene expression
or quantitative protein production does not imply causality. Therefore, additional studies are necessary
to characterize the exact molecular mechanisms of the IL22RA2 association signal in MS.
In summary, we successfully identified a comparatively rare genetic variant in IL22RA2 that is
strongly—and likely independently of the primary GWAS signal—associated with MS. It causes an
amino acid change in the signal peptide of IL-22BP and correspondingly, functional data generated for
this study suggest an inhibitory effect on the trafficking of IL-22BP. Functional research on this variant
will certainly provide insight about the role of this gene in MS and a better understanding of the still
fairly unexplored function of IL-22BP isoforms in the immune system.
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Abbreviations
AP Acetone precipitate
CL Cell lysate
EAE Experimental autoimmune encephalomyelitis
Cells 2020, 9, 175 15 of 23
EDSS Expanded Disability Status Scale
GWAS Genome-wide association screen
IL-22BPi1, 2 or 3 Interleukin 22 binding protein isoform-1, -2 or -3
IL22RA2 Interleukin 22 receptor subunit alpha 2
LD Linkage disequilibrium
MAF Minor allele frequency
OR Odds ratio
PP Primary progressive
RAF Risk allele frequency
RR Relapsing-remitting
ScP Secondary progressive
SFM Serum-free medium
SNP Single nucleotide polymorphism
SP Signal peptide
Appendix A
Table A1. Association values of all SNPs included in the fine mapping conditioned to the index SNP,
rs202573. 1 OR: odds ratio. 2 CI: confidence interval.
SNP OR 1 (95% CI 2) p
rs4896239 0.95 (0.798–1.131) 0.5638
rs17066096 1.059 (0.8746–1.282) 0.5569
rs12194034 1.025 (0.8412–1.249) 0.8055
rs1543509 0.9821 (0.7719–1.25) 0.8835
rs28366 1.047 (0.8594–1.275) 0.6497
rs276466 0.9779 (0.7803–1.225) 0.8458
rs10484798 0.8452 (0.6874–1.039) 01105
rs13217897 0.8249 (0.6608–1.03) 0.08906
rs2064501 0.8337 (0.6674–1.041) 0.109
rs11154914 1.043 (0.7864–1.384) 0.7687
rs28385692 1.799 (0.8654–3.739) 0.1158
rs13197049 0.846 (0.6766–1.058) 0.1423
rs6570136 0.8669 (0.7018–1.071) 0.1855
rs7745487 1.001 (0.7436–1.347) 0.9947
Table A2. Association values of the haplotypes in blocks. LD blocks were calculated with the confidence
interval method using Haploview [25,26].
Block Haplotype Frequency Case, Control Frequencies p
rs4896239 + rs28385692
TA 0.501 0.479, 0.519 0.102
CG 0.267 0.273, 0.262 0.6031
CA 0.232 0.248, 0.219 0.1642
rs12194034 +
rs1543509+rs28366 +
rs276466
TTTA 0.408 0.404, 0.411 0.763
TTTG 0.22 0.216, 0.224 0.7026
ATCA 0.217 0.215, 0.218 0.8637
TCTA 0.148 0.160, 0.139 0.2266
rs132117897 + rs202573
+ rs2064501 +
rs11154914 +
rs13197049
GGCAA 0.495 0.475, 0.512 0.1298
AGTAT 0.193 0.178, 0.206 0.1565
GATGA 0.172 0.192, 0.156 0.0561
GATAA 0.124 0.139, 0.111 0.0806
rs6570136 +rs7745487
GG 0.551 0.543, 0.558 0.5396
AG 0.278 0.265, 0.289 0.2853
AA 0.171 0.192, 0.153 0.0373
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Table A3. Features of the individual and consensus computational tools used in this study. Adapted from [42].
ID Server
Name
Individual or
Consensus Tool Website MLT That Based on Input Parameters Deleterious Threshold & Outputs Ref.
Meta RL &
Meta SVM Consensus
http://annovar.
openbioinformatics.org/en/
latest/
MMAF, linear kernel,
radial kernel and
polynomial kernel
A score of SIFT, PolyPhen-2, GERPþþ,
Mutation Taster, Mutation Assessor,
FATHMM, LRT, SiPhy and PhyloP
D (Deleterious), N (Neutral) and U
(Unknown) [50]
Meta-SNP Consensus http://snps.biofold.org/meta-snp/ RF
A score of PANTHER, PhD-SNP, SIFT,
and SNAP
Disease related or Polymorphic
non-synonymous SNVs [32]
PredictSNP Consensus https://loschmidt.chemi.muni.cz/predictsnp/
Weighted majority
vote consensus
A score of PolyPhen-1, PolyPhen-2, SIFT,
MAPP, PhD-SNP and SNAP Confidence scores and neutral or deleterious [31]
REVEL Consensus https:
//omictools.com/revel-tool RF
A score of MutPred, FATHMM, VEST,
Poly-Phen, SIFT, PROVEAN, Mutation
Assessor, Mutation Taster, LRT, GERP,
SiPhy, phyloP, and phastCons
Disease variants or rare neutral variants [51]
CADD Individual http://cadd.gs.washington.edu/score
A linear kernel
support vector
machine (SVM)
SNVs Functional, deleterious, and pathogenicvariants [52]
MAPP Individual
http://mendel.stanford.
edu/SidowLab/downloads/
MAPP/index.html
Physicochemical
properties and
alignment score
The original amino acid, the position of
the substitution and the new amino acid.
Score (0–1). The predicted is damaging if the
score <=0.05 and tolerated if the score >0.05 [53]
Mutation
Assessor Individual
http:
//mutationassessor.org/r3/ Conservation method
Genome build, chromosome position,
reference allele and substituted allele or
Protein ID and variant
(VC) Variant conservation score and (VS)
Variant specificity score. Level of functional
impact (high, medium, low, neutral)
[54]
SIFT Individual
http:
//sift.jcvi.org/www/SIFT_
help.html#SIFT_OUTPUT
Alignment scores The original amino acid, the position ofthe substitution and the new amino acid
Score (0–1). The predicted is damaging if the
score <=0.05 and tolerated if the score >0.05 [55]
SNAP2 Individual https://rostlab.org/services/snap2web/ ANN Protein sequence Non-neutral and neutral, Score and accuracy [56]
PANTHER Individual http://www.pantherdb.org/about.jsp
Alignment Scores
HMM Protein sequence and substitution
All GO annotations & Phylogenetic
annotation [57]
PhD-SNPg Individual http://snps.biofold.org/phd-snpg/method.html
Gradient boosting
algorithm
Chromosome position, and protein
variation (position, and first amino acid,
and second amino acid variant)
If the probability is >0.5 then the SNV is
predicted to be Pathogenic otherwise Benign [58]
Polyphen-2 Individual http://genetics.bwh.harvard.edu/pph2/ Empirical rules
Protein, SNP identifier or Protein
sequence in FASTA format and positions
of the substitution
Probably damaging or Benign, or Possibly
damaging, Sensitivity, specificity, Multiple
sequence alignment and 3D Visualization
[59]
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Figure A1. Linkage disequilibrium structure and haplotypes of IL22RA2. On the left, LD plot of the 
15 SNPs analyzed in the Bilbao cohort. Blocks were calculated using the confidence interval 
algorithm implemented in Haploview [25,26]. Only samples genotyped for all SNPs were considered 
for the haplotype calculation. The numbers inside the squares indicate r2 values, and darker shades 
of gray represent higher degrees of linkage disequilibrium. On the right, all the haplotypes that were 
present in the Bilbao cohorts considering all SNPs in a single LD block are represented. The only 
haplotype containing the risk (C) allele of the non-synonymous SNP rs28385692 is boxed. SNPs with 
significant associations and rs28385692 are indicated on top of the right panel. 
 
Figure A2. Haplotypes formed by the three SNPs genotyped in the Basque Country, Madrid, 
Andalucía, Barcelona and Germany populations. The three SNPs were considered in a single 
haplotype block. On the left, LD plot showing pairwise r2 values between the SNPs. On the right, the 
5 SNP haplotypes present in the combined cohorts. The only haplotype containing the C allele of 
rs28385692 is boxed. 
Figure A1. Linkage disequilibrium structure and haplotypes of IL22RA2. On the left, LD plot of the 15
SNPs analyzed in the Bilbao cohort. Blocks were calculated using the confidence interval algorithm
implemented in Haploview [25,26]. Only samples genotyped for all SNPs were considered for the
haplotype calculation. The numbers inside the squares indicate r2 values, and darker shades of gray
represent higher degrees of linkage disequilibrium. On the right, all the haplotypes that were present
in the Bilbao cohorts considering all SNPs in a single LD block are represented. The only haplotype
containing the risk (C) allele of the non-synonymous SNP rs28385692 is boxed. SNPs with significant
associations and rs28385692 are indicated on top of the right panel.
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Figure A2. Haplotypes formed by the three SNPs genotyped in the Basque Country, Madrid, Andalucía,
Barcelona and Germany populations. The three SNPs were considered in single haplotype block.
O the left, LD plot showing pairwise r2 val es between the SNPs. On the right, the 5 SNP haplotypes
present in the combined cohorts. The only haplotype containing the C allele of rs28385692 is boxed.
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Figure A3. The pathogenicity prediction of rs28385692 using PredictSNP (a), Meta-SNP (b), and (c) 
Ensemble VEP web servers. The results indicate the predictive severity of the p.Leu16Pro variant 
conferred by the SNP rs28385692 for the three IL-22BP isoforms. 
 
IL-22BPi1
IL-22BPi2
IL-22BPi3
IL-22BPi1
IL-22BPi2
IL-22BPi3
IL-22BPi1
IL-22BPi2
IL-22BPi3
(a)
(b)
(c)
PredictSNP
Meta-SNP
Ensemble
Figure A3. The pathogenicity prediction of rs28385692 using PredictSNP (a), Meta-SNP (b), and (c)
Ensemble VEP web servers. The results indicate the predictive severity of the p.Leu16Pro variant
conferred by the SNP rs28385692 for the three IL-22BP isoforms.
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Figure A4. Signal peptide prediction in the Leu16 and Pro16 variant IL-22BP proteins. SignalP 5.0, 
PrediSi and Signal-3L predicted the cleavage site for both wild-type and p.Leu16Pro mutant to be the 
21st residue of the signal peptide. Panels (a–c) show cleavage sites from SignalP 5.0, PrediSi and 
Signal-3L, respectively. Panels (d,e) represent the secondary structure predictions from RaptorX and 
SABLE, respectively. 
 
Figure A5. Leu16 to Pro mutation in the signal peptide of IL-22BPi2 is associated with lower 
intracellular levels. HEK293 cells were transfected with the IL22RA2v2 wild type (Leu16), mutant 
(16P) or empty expression plasmids; 24 h later cells were fixed, permeabilized and immunostained 
with anti-IL22BP antibody. Cells were analyzed by flow cytometry. 
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Signal-3L, respectively. Pa l , t t e secondary structure predictions from RaptorX and
SABLE, respectively.
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Figure A5. Leu16 to Pro mutation in the signal peptide of IL-22BPi2 is associated with lower intracellular
levels. HEK293 cells were transfected with the IL22RA2v2 wild type (Leu16), mutant (16P) or empty
expression plasmids; 24 h later cells were fixed, permeabilized and immunostained with anti-IL22BP
antibody. Cells were analyzed by flow cytometry.
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